Pilot Study of RR-HNK in OCD ((HNKO))

This double-blind, placebo-controlled trial (n=45) will assess the safety and efficacy of two doses of intravenous (2R,6R)-Hydroxynorketamine (RR-HNK) in adults with obsessive-compulsive disorder (OCD). Participants will receive either 17.5mg/70kg or 35mg/70kg of RR-HNK, or a placebo, via a single infusion.

Led by Dr Carolyn Rodriguez at Stanford University, this study aims to understand how RR-HNK affects the brain and whether it can reduce OCD symptoms.

Participants, aged 18–65, must have a confirmed OCD diagnosis and have either failed at least one prior standard OCD treatment (such as serotonin reuptake inhibitors or cognitive-behavioural therapy) or declined these treatments. EEG and behavioural tests will be conducted before and after the infusion to assess changes in OCD severity, measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS). The trial is funded by the National Institutes of Health (NIH) and is expected to run from December 2024 to November 2029.

Topic Obsessive-Compulsive Disorder Neuroscience
Compound Ketamine Placebo
Country United States of America
Visit trial
Status Not yet recruiting
Results Published No
Start date 01 December 2024
End date 30 November 2029
Phase Phase I Phase II
Design Blinded
Type Interventional
Generation Second
Participants 45
Sex All
Age 18- 65
Therapy No

Trial Details

The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms. This protocol examines the safety and efficacy of 2 dosage levels of intravenous RR-HNK administration in individuals with OCD.

Trial Number NCT06575075

Sponsors & Collaborators

Stanford University
Researchers at Stanford are exploring the potential of ketamine, MDMA and psilocybin by connecting neuroscience, psychiatry and anesthesiology.

National Institutes of Health
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.